CN

Shuguo SunSUN SHU GUO

Professor    Supervisor of Doctorate Candidates    Supervisor of Master's Candidates

  • Professional Title:Professor
  • Gender:Male
  • Status:Employed
  • Department:School of Basic Medical Sciences
  • Education Level:Postgraduate (Doctoral)
  • Degree:Doctoral Degree in Science

Paper Publications

Current position: 英文主页 > Scientific Research > Paper Publications

Interferon-γ induces tumor resistance to anti-PD-1 immunotherapy by promoting YAP phase separation

Release time:2021-02-20
Hits:
Indexed by:
Journal paper
First Author:
Man Yu,Zhengxin Peng
Correspondence Author:
Shuguo Sun
Co-author:
Min Qin,Yang Liu,Jingning Wang,Cai Zhang,Jiaming Lin,Tianqi Dong,Lulu Wang,Shasha Li,Yongqin Yang,Shan Xu,Wencong Guo,Xiao Zhang,Mingjun Shi,Huiming Peng,Xianwen Luo,Huixia Zhang,Li Zhang,Yan Li,Xiang-Ping Yang
Journal:
Molecular Cell
Included Journals:
SCI
Place of Publication:
美国
Date of Publication:
2021-02-20
Impact Factor:
15.0
Abstract:
Summary Interferon-γ (IFN-γ)-mediated adaptive resistance is one major barrier to improving immunotherapy in solid tumors. However, the mechanisms are not completely understood. Here, we report that IFN-γ promotes nuclear translocation and phase separation of YAP after anti-PD-1 therapy in tumor cells. Hydrophobic interactions of the YAP coiled-coil domain mediate droplet initiation, and weak interactions of the intrinsically disordered region in the C terminus promote droplet formation. YAP partitions with the transcription factor TEAD4, the histone acetyltransferase EP300, and Mediator1 and forms transcriptional hubs for maximizing target gene transcriptions, independent of the canonical STAT1-IRF1 transcription program. Disruption of YAP phase separation reduced tumor growth, enhanced immune response, and sensitized tumor cells to anti-PD-1 therapy. YAP activity is negatively correlated with patient outcome. Our study indicates that YAP mediates the IFN-γ pro-tumor effect through its nuclear phase separation and suggests that YAP can be used as a predictive biomarker and target of anti-PD-1 combination therapy.